Karyopharm Therapeutics (NASDAQ:KPTI) is a commercial‐stage pharmaceutical company dedicated to discovering, developing and commercializing novel first‐in‐class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Founded in 2008 and headquartered in Newton, Massachusetts, the company pioneered the concept of selective inhibitors of nuclear export (SINE), a therapeutic approach that addresses the dysregulation of nuclear transport pathways implicated in cancer cell survival and proliferation.
The company’s lead product, XPOVIO (selinexor), is an oral SINE compound approved in multiple jurisdictions for various hematologic malignancies, including relapsed or refractory multiple myeloma and certain forms of non‐Hodgkin lymphoma. Beyond selinexor, Karyopharm’s pipeline comprises next‐generation SINE compounds such as eltanexor (KPT-8602), which is being evaluated in additional hematologic and solid tumor indications, and other novel molecules targeting oncogenic pathways and inflammatory conditions.
Karyopharm conducts clinical trials across North America, Europe and Asia and collaborates with academic centers, cooperative oncology groups and industry partners to expand the applications of its therapeutic platforms. The company holds regulatory approvals in the United States, European Union, Canada and other territories, and continues to pursue label expansions and new indications through ongoing studies and strategic alliances.
The leadership team is led by President and Chief Executive Officer Steven K. Danehy, whose tenure has focused on global commercialization and pipeline advancement. Co-founder and Chief Scientific Officer Dr. Sharon Shacham continues to spearhead research initiatives, while a multidisciplinary management team oversees clinical development, regulatory affairs and manufacturing operations as Karyopharm advances its mission to deliver innovative therapies to patients worldwide.
